# Muscle Cathepsin B Treatment Improves Behavioral and Neurogenic Deficits in a Mouse Model of Alzheimer's Disease

## TL;DR

Injecting a muscle enzyme called Cathepsin B in mice with Alzheimer's improved memory and brain cell growth without affecting plaque buildup.

## Contribution

This study shows that targeting muscle with Cathepsin B can improve cognitive and neurogenic deficits in Alzheimer's disease models.

## Key findings

- Muscle-targeted Cathepsin B treatment improved memory and adult hippocampal neurogenesis in Alzheimer's mice.
- Proteomic profiles in the hippocampus, muscle, and plasma of treated Alzheimer's mice resembled those of healthy controls.
- Cathepsin B treatment enhanced protein synthesis and metabolic processes in Alzheimer's mice.

## Abstract

Increasing evidence indicates skeletal muscle function is associated with cognition. Muscle‐secreted protease Cathepsin B (Ctsb) is linked to memory in animals and humans, but has an unclear role in neurodegenerative diseases. To address this question, we utilized an AAV‐vector‐mediated approach to express Ctsb in skeletal muscle of APP/PS1 Alzheimer's disease (AD) model mice. Mice were treated with Ctsb at 4 months of age, followed by behavioral analyses 6 months thereafter. Here we show that muscle‐targeted Ctsb treatment results in long‐term improvements in motor coordination, memory function, and adult hippocampal neurogenesis, while plaque pathology and neuroinflammation remain unchanged. Additionally, in AD mice, Ctsb treatment normalizes hippocampal, muscle, and plasma proteomic profiles to resemble that of wildtype (WT) controls. In AD mice, Ctsb increases the abundance of hippocampal proteins involved in mRNA metabolism and protein synthesis, including those relevant to adult neurogenesis and memory function. Furthermore, Ctsb treatment enhances plasma metabolic and mitochondrial processes. In muscle, Ctsb treatment elevates protein translation in AD mice, whereas in WT mice mitochondrial proteins decrease. In WT mice, Ctsb treatment causes memory deficits and results in protein profiles across tissues that are comparable to AD control mice. Overall, the biological changes in the treatment groups are consistent with effects on memory function. Thus, skeletal muscle Ctsb application has potential as an AD therapeutic intervention.

Targeting muscle with Cathepsin B (Ctsb) to treat the AD mouse brain. In this study, an AAV‐vector‐mediated approach, utilized to express Ctsb in muscle, prevented mnemonic and neurogenic deficits and normalized hippocampal, muscle, and plasma proteomic profiles.